The Cytometry and Antibody Technology (CAT) Facility?s mission is to support the community of researchers at the University of Chicago with: 1) cutting-edge technology operated by expertly trained personnel; 2) high- quality analytical monoclonal antibodies; and 3) expert technical consultation and training of researchers. The Facility is utilized by University of Chicago Medicine Comprehensive Cancer Center (UCCCC) investigators conducting basic and translational research of cellular phenotype and function. The CAT Facility serves the UCCCC membership by providing tools necessary to measure the properties of cells and their products. This includes the technology and staff expertise to use these reagents for experimental measurements (flow cytometers, mass cytometer, image cytometers, cell sorters and multiplex analyzers), as well as reagents used to label the cells (antibody/hybridoma bank that provides commonly used, highest quality purified antibodies, purification of existing monoclonals, and fluorescently coupled antibodies). Multiparameter analysis of single cells has become a standard tool in cancer research. Flow cytometry technology now allows for the measurements of more than 15 different markers simultaneously. With imaging flow cytometry (e.g., Amnis ImageStream), the CAT Facility can also capture images of the analyzed cells and develop clinical or research assays based on the expression of these markers as well as on their distribution. With mass cytometry, more than 40 parameters on a single cell can be measured to obtain an unequalled amount of information for each and every cell analyzed. Specific Core accomplishments during the current funding period include obtaining a new BD FACsFortessa for 15 color flow cytometry, an Aria Fusion for sorting human samples for translational studies, and a new CyTOF Helios mass cytometer that was funded by a successful NIH S10 award. The Facility?s Scientific and Technical Directors provide direct oversight of the operation of the CAT Facility. A Faculty Oversight Committee (FOC) also provides an advisory role to the Facility personnel with regards to services, scientific direction and fiscal issues. The Office of Shared Research Facilities (OSRF) serves as the home department for the Facility, providing IT and HR support, accountancy services, and strategic planning. The Research Resources Oversight Committee (RROC) is a faculty committee that provides scientific and financial oversight of all BSD Cores, and provides long-term strategic planning of Core services and resources. Future plans for the CAT facility include improving direct contact with the research community to present information about the Facility and better understand the needs of our user base, development of CyTOF panels and reagents, and advancing as a cutting edge facility by incorporating new technology, while providing our successful base core services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-44
Application #
9701135
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395
Boisclair Lachance, Jean-François; Webber, Jemma L; Hong, Lu et al. (2018) Cooperative recruitment of Yan via a high-affinity ETS supersite organizes repression to confer specificity and robustness to cardiac cell fate specification. Genes Dev 32:389-401
Kudron, Michelle M; Victorsen, Alec; Gevirtzman, Louis et al. (2018) The ModERN Resource: Genome-Wide Binding Profiles for Hundreds of Drosophila and Caenorhabditis elegans Transcription Factors. Genetics 208:937-949
Maron, Steven B; Alpert, Lindsay; Kwak, Heewon A et al. (2018) Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov 8:696-713
Kane, Melissa; Deiss, Felicity; Chervonsky, Alexander et al. (2018) A Single Locus Controls Interferon Gamma-Independent Antiretroviral Neutralizing Antibody Responses. J Virol 92:
Zeineddine, Hussein A; Girard, Romuald; Saadat, Laleh et al. (2018) Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest :
Gamazon, Eric R; Trendowski, Matthew R; Wen, Yujia et al. (2018) Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Sci Rep 8:733
Xiao, Annie; Crosby, Jennie; Malin, Martha et al. (2018) Single-institution report of setup margins of voluntary deep-inspiration breath-hold (DIBH) whole breast radiotherapy implemented with real-time surface imaging. J Appl Clin Med Phys 19:205-213
Day, Kasey J; Casler, Jason C; Glick, Benjamin S (2018) Budding Yeast Has a Minimal Endomembrane System. Dev Cell 44:56-72.e4
Girard, Romuald; Zeineddine, Hussein A; Koskimäki, Janne et al. (2018) Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res 122:1716-1721

Showing the most recent 10 out of 668 publications